In 2026, the Society for Cardiovascular Angiography & Interventions (SCAI), in conjunction with the Canadian Association of Interventional Cardiology (CAIC-ACCI), hosted a landmark international conference titled the SCAI Scientific Sessions 2026 & CAIC-ACCI Summit. This pivotal gathering, held from April 23 to April 25 at the Palais des Congrès de Montréal, Canada, convened over 1,900 of the global interventional cardiology community’s leading minds—including clinicians, researchers, and innovators—who came together to dissect cutting-edge developments in interventional cardiology and endovascular medicine. The conference featured more than 500 faculty members and the presentation of 810 abstract submissions, signaling the vast scale and significance of advancements discussed.
At the core of this gathering was the SCAI’s mission to foster scientific innovation, policy advancement, and professional growth within cardiovascular intervention. With cardiovascular disease claiming close to one million lives annually across North America alone—surpassing fatalities caused by respiratory diseases and cancers combined—the urgency to deepen understanding and refine intervention techniques in this arena cannot be overstated. The multidisciplinary sessions spanned coronary artery disease, structural heart disease, peripheral artery disease, pharmacotherapy, and even considerations emerging from the COVID-19 pandemic’s cardiovascular impacts.
A prominent focus lay on coronary heart disease, the most prevalent form of cardiovascular illness worldwide. Experts presented new clinical trials and evidence aimed at refining the acute management of myocardial infarctions and cardiogenic shock. Notably, the SELUTION DeNovo Trial unveiled data on Sirolimus Eluting Balloons for acute coronary syndrome patients, potentially redefining percutaneous intervention methods with drug-eluting balloon technologies targeted at reducing restenosis and revascularization rates. Additional presentations delved into strategies for reducing mortality in cardiogenic shock and identifying clinically important subgroups post-STEMI utilizing data from large-scale registries and randomized trials.
Structural heart disease, affecting millions globally, formed another critical topic area. The Scientific Sessions highlighted technological advancements such as transcatheter mitral valve replacement with devices like the AltaValve—a transcatheter prosthetic featuring atrial fixation designed to improve procedural feasibility and one-year patient outcomes in mitral valve interventions. These innovations could revolutionize therapy by making structural interventions less invasive, reducing surgical risks, and expanding treatment candidacy among high-risk patients previously limited by anatomy or comorbidity burdens.
Pharmacotherapy research underscored its integral role in cardiovascular treatment regimens. Presenters discussed the unaddressed residual risk in lipid management elucidated by elevated Lipoprotein(a) levels, based on rigorous analysis from NIH randomized trials. Such insights drive the refinement of lipid-lowering protocols beyond conventional LDL cholesterol targets. Additional data on the impact of SGLT2 inhibitors post-percutaneous coronary intervention (PCI) in patients exhibiting type 2 diabetes mellitus and coronary artery disease provided compelling evidence for integrating these agents into comprehensive secondary prevention strategies.
Peripheral artery disease (PAD) emerged as a critical area given its prevalence—affecting an estimated 10 million adults over 40 in the United States alone—and its status as the leading cause of limb amputation worldwide. The conference showcased novel interventional approaches like transcatheter arterialization of deep veins for chronic limb-threatening ischemia (CLTI), as demonstrated in the PROMISE III study, which assessed quality of life and clinical outcomes at six months post-procedure. Comparisons between radial-to-peripheral versus traditional femoral access for PAD revascularization in the CARPOOL study further revealed procedural nuances impacting patient recovery and complication rates.
The lingering cardiovascular ramifications of the COVID-19 pandemic were addressed with emerging registry data providing longitudinal insights into one-year outcomes for patients experiencing ST-segment elevation myocardial infarction (STEMI) concurrent with COVID-19 infection. Such studies contribute to clarifying whether the pandemic catalyzed increased myocardial infarction rates through viral pathology or indirect effects, shaping future post-discharge risk stratification and secondary prevention algorithms.
Beyond clinical trials and device trials, the summit fostered vital cross-border collaboration, emphasizing the integration of multidisciplinary professional knowledge to elevate care standards globally. Leaders from both SCAI and CAIC-ACCI accentuated the importance of combining rigorous education, comprehensive research, and shared innovation to empower cardiology professionals in making evidence-based, patient-centered decisions, ultimately translating into improved clinical outcomes.
This edition of the Scientific Sessions solidified SCAI’s role at the vanguard of interventional cardiology advancement, delivering an expansive program rich with live case demonstrations, featured clinical research, and novel guideline presentations. The seamless cooperation between American and Canadian interventional communities exemplifies international synergy, strengthening the collective capacity to tackle cardiovascular health’s evolving challenges.
For participants at all career stages—from fellows to seasoned experts—the conference provided unparalleled opportunities for professional development through leadership sessions, networking, and exposure to translational science bridging bench discovery with bedside application. As the prevalence of cardiovascular diseases continues to impose profound individual and societal burdens, the acceleration of innovation and knowledge dissemination remains imperative.
In sum, the SCAI Scientific Sessions 2026 & CAIC-ACCI Summit represented more than an academic convention; it symbolized the unrelenting pursuit of excellence in cardiovascular intervention. By elucidating novel therapeutics, optimizing procedural strategies, and exploring emerging disease intersections such as COVID-19, the summit accentuated the dynamic evolution within interventional cardiology poised to improve patient lives worldwide.
Subject of Research: Interventional cardiology advancements, clinical outcomes in coronary and structural heart diseases, peripheral artery disease treatment, pharmacotherapy in cardiovascular disease, and cardiovascular impacts of COVID-19.
Article Title: Breakthroughs and Innovations in Interventional Cardiology Spotlighted at SCAI Scientific Sessions 2026 & CAIC-ACCI Summit
News Publication Date: April 8, 2026
Web References:
https://www.scai.org/education-and-events/events-schedule/scai-2026-scientific-sessions-caic-acci-summit
https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html
Image Credits: Society for Cardiovascular Angiography & Interventions and Canadian Association of Interventional Cardiology
Keywords: Interventional Cardiovascular Medicine, Coronary Heart Disease, Structural Heart Disease, Peripheral Artery Disease, Pharmacotherapy, COVID-19 Cardiovascular Impact, Transcatheter Mitral Valve Replacement, Sirolimus Eluting Balloons, SGLT2 Inhibitors, Cardiogenic Shock, Late-Breaking Clinical Trials, Cardiovascular Innovation
Tags: cardiovascular angiography innovationscardiovascular pharmacotherapy developmentscoronary artery disease researchCOVID-19 cardiovascular impactsendovascular medicine breakthroughsglobal cardiovascular disease statisticsinternational cardiology conference 2026interventional cardiology advancementsmultidisciplinary cardiology sessionsperipheral artery disease interventionsprofessional growth in cardiologystructural heart disease treatments
